Vertex Releases Promising Data on VX-661 and IvacaftorThe combination of VX-661 and ivacaftor led to a significant improvement in lung function in adults with CF due to two F508del CFTR mutations. Twenty eight days of therapy led to a 7.5-9% relative increase in FEV 1 compared to a 0.03% increase in those taking a placebo. Click here for more information. Webcast with Tiffany Christensen Is Available Please watch the presentaion entitled “ Living and Thriving with Cystic Fibrosis” given by Tiffany Christensen, a nationally recognized speaker and author of “ Sick Girl Speaks”. Tiffany has cystic fibrosis and has received two life-saving lung transplants. She spoke from the perspective of a patient with cystic fibrosis and a professional patient advocate. Click here for the link. | | | | |
|